Real-World Data Or Studies Of Competitor Drugs Can Serve As Confirmatory Evidence For US FDA
Executive Summary
Draft guidance describes seven types of confirmatory evidence that can be used with one adequate and well-controlled clinical study to demonstrate substantial evidence of effectiveness, including evidence from expanded access, real-world data, and studies of other drugs in the same class.
You may also be interested in...
What ‘Confirmatory Evidence’ Does US FDA Need When Sponsors Want To Rely On A Single Trial?
Amylyx’s Relyvrio survival data, drawn from a post hoc exploratory survival analysis of randomized patients, and the primary ALS functional endpoint ‘capture distinct concepts,’ FDA states. Use of long-term survival data from the same trial as confirmatory evidence was unusual, but not unique.
FTC Commissioner Recusal Decisions Should Be Public, US Chamber Of Commerce Says
Chamber files petition to have FTC amend its disqualification rules to have commissioners explain their rejection of recusal requests. FTC is seeking public comments on the petition.
FTC Merger Guidelines Cast ‘Perilous Shadow’ Over Biopharma
BIO objects to guidelines seeking to block mergers that would eliminate a potential entrant in a concentrated market and give greater scrutiny to transactions that are part of a series of company deals. APhA and NCPA call for FTC to consider more factors in PBM mergers.